Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

Expert Rev Clin Immunol. 2016 Oct;12(10):1109-21. doi: 10.1080/1744666X.2016.1188006. Epub 2016 Jun 1.

Abstract

Introduction: Treatment and prevention are of critical importance in patients with cutaneous lupus erythematosus (CLE), as the disease can have a devastating effect on patient well-being and quality of life.

Areas covered: We conducted a selective search of the PubMed database for articles published between December 2010 and November 2015. This review encompasses both non-pharmaceutical (photoprotection, smoking cessation, drug withdrawal, and vitamin D replacement) and pharmaceutical (topicals, antimalarials, immunosuppressives, biologics, etc.) interventions used in the treatment of CLE. Expert Commentary: Recent work has expanded our understanding of established therapies as well as introduced new treatments for consideration, though existing medications still prove inadequate for a subset of patients. Changes in trial design may help to alleviate this issue.

Keywords: Cutaneous Lupus Erythematosus Disease Area and Severity IndexTM (CLASITM); Cutaneous lupus erythematosus; antimalarials; biologics; immunomodulators; immunosuppressives; topical calcineurin inhibitors.

Publication types

  • Review

MeSH terms

  • Animals
  • Calcineurin Inhibitors / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Cutaneous / therapy*
  • Phototherapy*
  • Smoking Cessation
  • Vitamin D / therapeutic use*
  • Withholding Treatment

Substances

  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • Vitamin D